Grupo Indukern in facts

Transcription

1 PRESS RELEASE

2 Grupo Indukern in facts Multinational family-owned group. Founded in 1962 by José Luis Díaz-Varela. Comprises three main companies: o Indukern (1962) chemical sector o Calier (1968) veterinary laboratory o Kern Pharma (1999) pharmaceutical laboratory Consolidated turnover of 725 milion: o Indukern: 429 million o Calier: 74 million o Kern Pharma: 240 million International operations account for 53% of the group s business, while Spanish operations account for 47%. Subsidiaries in 17 countries. Markets its products in over 80. A workforce of over 1,700 staff worldwide. Headquarters in Barcelona.

3 Grupo Indukern: A diverse, international group in continuous expansion Grupo Indukern was created in 1962 as a small, family-run business. Its founder José Luis Díaz-Varela, an entrepreneur with an international vision, chose to base the company in Barcelona, a port city, with considerable industrial infrastructure and a strong presence in the chemical, pharmaceutical and veterinary industries. The business originally focused on the distribution of chemical products with a clear mission to become a leading company thanks to its excellent production processes and prime quality products. Business diversification, international expansion and exploitation of opportunities in the countries where it currently operates have been the keys to the company s success and constant growth in markets and products. Grupo Indukern currently comprises three main companies that operate primarily with basic necessity products: Indukern, dedicated to the distribution of chemicals and higher value-added activities including formulation, production and technical advice for various industrial sectors; Calier, whose activity is focused on researching, developing, manufacturing and marketing pharmacological and biological products for veterinary use; and Kern Pharma, a pharmaceutical laboratory dedicated to generic medicine, biosimilar products, self-care products, women s health products, sports nutrition and health, and production for other companies. Currently, the company bills 725 million, with 53% of sales pertaining to external markets and 47% to the Spanish market. With over 1,700 employees worldwide, the company has branches in 17 different countries and products marketed in over 80. Grupo Indukern s headquarters in Barcelona

4 Indukern, global leader in fine chemical distribution Indukern is the embryo of what is today known as Grupo Indukern. It is currently a key player in the areas of fine chemistry marketing and distribution and higher valueadded activities of formulation, production and technical advice for various industry sectors. Its activity revolves around three lines of business: Intermediation between suppliers of raw materials and manufacturers of finished products in sectors such as human food, flavourings and fragrances, pharmacy, veterinary and animal nutrition and industrial chemical products. Representative of some of the leading global manufacturers in the sectors in which it operates. Development of its own products, which are adapted to meet our clients needs thanks to a profound knowledge of the market, and its technical advice services. Indukern s turnover reaches 429 million. International operators make up 62% and 36% from Spain. With a workforce of over 450 employees, it has subsidiaries in Brazil, China, Colombia, India, Mexico, Portugal, the Dominican Republic and Switzerland and is present via representation in Bulgaria, France, Italy, Poland, Czech Republic and Romania. Additionally, its presence in China and other developing countries offers its valuable access to certain ingredients, and enables it to provide a wide range of products to global and local clients. The company is leader in markets such as Brazil and Mexico. In Brazil, it reinforced its presence with the acquisition at the beginning of 2016 of 75% of Brazilian company Hexus Food Ltda., focused in development and marketing of ingredients and solutions for the chemical industry. At the beginning of 2017 in Mexico, the company bought Cytecsa, a leading company in the Aztec country in the development and marketing of premixes and technology solutions for the dairy, cheese and ice cream industry. Indukern has five divisions: Animal Nutrition and Veterinary, Flavours and Fragrances (F&F), Food Ingredients, Industrial Chemistry and Pharmaceutical Ingredients. The clear mission in each division is to be more than mere intermediaries in the supply chain; to offer clients company products and associated services as well as significant expertise and extensive penetration in their markets.

5 In the distribution sector, logistics is the key to offering a competitive advantage. That is the reason why Indukern provides an extensive infrastructure around the world, to enable them to meet the needs of their clients on a national and international level. In Spain, Indukern has facilities in Burgos, Fuenlabrada (Madrid), Sentmenat (Barcelona) and the Logistics Activities Area (ZAL) at the Port of Barcelona. Specifically in ZAL, Indukern has a Research and Development Centre, which comprises a laboratory and two pilot plants where it designs and produces food solutions for dairy products, cheese, drinks, processed meat, pastries, bread and sauces for the Food Division. In ZAL, the Flavours and Fragrances (F&F) Division has an innovative laboratory for raw materials development and quality assurance. Indukern has also facilities in Hamburg (Germany), Jundaí (Brazil) the largest logistics platform in Latin America and Jalisco (Mexico). Indukern s logistic facilities in the Logistics Activities Area (ZAL) at the Port of Barcelona Calier, committed to animal health and welfare Calier specializes in the research, development, registration and marketing of pharmacological and biological products for veterinary use. Currently, the company has more than 1,400 products registered in 80 countries worldwide, of which more than a hundred were developed internally and these are destined for livestock and pets. In 2016, the consolidated billing of Calier amounted to 74 million, with 77% sales pertaining to external markets, while 24% corresponded to the Spanish market. All of this activity is possible thanks to a highly specialized workforce of 400 employees, the latest technology, state-off-the-art development and manufacturing facilities in Les Franqueses del Vallès (Barcelona), which complies with Good Manufacturing Practices (GMP) regulations, and a development and production centre in León.

6 Calier also has a production centre in Montevideo (Uruguay) and another one in Cali (Colombia), after the acquisition of Laboratorios Laverlam, focused in research, development, manufacture and commercialization of Biological products for Agricultural, Livestock and Aviculture industries. The company has manufacturing agreements in Morocco and Argentina and subsidiaries in Germany, Argentina, Colombia, Italy, Morocco, Mexico, Poland, Portugal, the Dominican Republic, Uruguay and Venezuela. The company s growth strategy includes continuing to promote its internationalization drive through organic growth or acquisitions- as well as extending its current product portfolio and focusing on the development and marketing of biological products for veterinary use. Calier was the first laboratory in the market to launch an avian vaccination against Salmonella enteritidis entirely developed in Spain, making it one the pioneers at the forefront of avian biological products. Currently, the company is investing almost 20 million to convert its facilities in León into a state-of-the-art plant in the research and development of biological medicines for animal health. The Calier premises in Les Franqueses del Vallès (Barcelona)

7 Kern Pharma, a diversified pharmaceutical laboratory Kern Pharma is a diversified pharmaceutical laboratory providing solutions for patients, to improve their health and quality of life, for doctors and pharmacists though a broad range of medication, while contributing towards the sustainability of the social-health system. Its vade mecum comprises 200 products in over 570 formats. Today, its activity revolves around six main lines of business: Generic: the company s generic drug portfolio includes 145 molecules in over 450 formats that cover 90% of prescription needs in 18 therapeutic areas. On average, the laboratory launches 25 new drugs each year (in 2016, it launched 22 new products and 34 new formats). Some of its products are market leaders, such as Kern Pharma Paracetamol and Ibuprofen. Currently, Kern Pharma is the fourth generic drug laboratory in Spain in terms of volume of turnover. Kern Pharma Consumer: Under this brand name, the company markets nonprescription drugs, non-financed prescription drugs and self-care products. A remarkable novelty is Ibudol, the first oral solution ibuprofen in stick pack marketed in Spain. Kern Pharma Biologics: The division of Kern Pharma is focused on biosimilar medication. The company was the first Spanish laboratory to market the first biosimilar monoclonal antibody (mab) authorized by the European Medicines Agency (EMA) Remsima -, thanks to the agreement reached with Korean biopharmaceutical company Celltrion Healthcare. It has also been the first to market Truxima, the first biosimilar of rituximab. Gynea: Under this brand, Kern Pharma markets products for the women s health products division, with and extensive portfolio in the area of gynecology. Finisher : Focused on sports nutrition and health, this is a range of products especially designed for before, during and after physical activity for people who maintain a healthy lifestyle and athletes who require nutritional supplements adapted to their needs. Production for other companies: Kern Pharma has always enjoyed a good relationship with important companies in the sector who have assigned them to manufacture their products.

8 With a workforce of 800 people, Kern Pharma bills 240 million, 72% of which corresponds to Spain and 28% to international markets. Today, the company has a branch in Portugal PharmaKern- and another one in the United States, after the acquisition of Granard Pharmaceuticals which primarily focuses on generic drug distribution. Kern Pharma also markets its products in Europe, Asia and Latin America. Kern Pharma s extensive facilities of 59,000m 2 in Terrassa (Barcelona) comprise a production plant, a logistics centre, and chemistry plant, laboratories and an office area. It produces in excess of 100,000 units per year, thanks to sophisticated automated machinery used for the production and distribution of products. This places Kern Pharma in 3 rd position in the ranking of manufacturing laboratories of generics in Spain per volume of units, and as trustworthy supplier for recognized companies in the sector who appoint them for the manufacture if their products. Picture of one of the packaging lines in the Kern Pharma production line in Barcelona From the outset, the company has always backed innovation, quality and continued investment in research and development, working to constantly improve its products and offer greater added value to professionals and patients alike. The company s growth strategy for the coming years will revolve around its established business lines in other words, generics, self-care, biosimilar products, women s health, sports nutrition and health, and manufacturing for other companies where it aims to increase turnover. The laboratory also has a major commitment to driving its Strategy and Development Area, made up for a team of more than 60 people and in which it invested 8.3 million in Its objective is to develop new products and improve those that already part of its vade mecum via new pharmaceutical technologies. Moreover, the company also has plans to continue investing in its facilities and expanding and improving the laboratory facilities at its plant in Terrassa.

9 Representatives Raúl Díaz-Varela Executive Vice President of Grupo Indukern CEO of Kern Pharma A degree in Business Science, MBA from ESADE and Master in Foreign Trade from the Community of European Management Schools (CEMS) in St. Gallen, Switzerland. He has dedicated his entire career to the family business, within the chemicalpharmaceutical industries at Grupo Indukern, in managerial positions in Industrial Kern Spain, and Indukern in Asia, Switzerland and Hong Kong. Since 1999, the year Kern Pharma was founded, he has directed the pharmaceutical side of the Group. He is president of the AESEG, which governs the generic drug industry in Spain.

10 For further information, please contact: Mercè Mascarell Atrevia Press Office at Grupo Indukern Susana Vilas Communications Director of Grupo Indukern